Profund Advisors LLC Fate Therapeutics Inc Transaction History

Profund Advisors LLC

  • $2.59 Billion
  • Q3 2024

A detailed history of Profund Advisors LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Profund Advisors LLC holds 42,652 shares of FATE stock, worth $69,096. This represents 0.01% of its overall portfolio holdings.

Number of Shares
42,652
Previous 46,528 8.33%
Holding current value
$69,096
Previous $152,000 1.97%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
SELL
$3.12 - $5.57 $12,093 - $21,589
-3,876 Reduced 8.33%
42,652 $149,000
Q2 2024

Aug 13, 2024
SELL
$3.26 - $7.08 $214,582 - $466,026
-65,823 Reduced 58.59%
46,528 $152,000
Q1 2024

May 08, 2024
BUY
$3.54 - $8.35 $397,722 - $938,130
112,351 New
112,351 $824,000
Q2 2023

Aug 10, 2023
SELL
$4.76 - $6.59 $398,545 - $551,767
-83,728 Reduced 32.84%
171,261 $815,000
Q1 2023

May 11, 2023
BUY
$4.24 - $11.12 $1.03 Million - $2.71 Million
243,798 Added 2178.52%
254,989 $1.45 Million
Q4 2022

Feb 02, 2023
BUY
$9.86 - $23.83 $2,257 - $5,457
229 Added 2.09%
11,191 $112,000
Q3 2022

Nov 04, 2022
SELL
$21.04 - $36.06 $4,039 - $6,923
-192 Reduced 1.72%
10,962 $246,000
Q2 2022

Aug 01, 2022
SELL
$17.78 - $42.39 $24,127 - $57,523
-1,357 Reduced 10.85%
11,154 $276,000
Q1 2022

May 10, 2022
SELL
$29.67 - $60.28 $41,538 - $84,392
-1,400 Reduced 10.06%
12,511 $485,000
Q4 2021

Feb 08, 2022
SELL
$47.84 - $64.34 $75,778 - $101,914
-1,584 Reduced 10.22%
13,911 $814,000
Q3 2021

Nov 12, 2021
BUY
$59.27 - $95.73 $778,867 - $1.26 Million
13,141 Added 558.24%
15,495 $918,000
Q2 2021

Aug 12, 2021
BUY
$67.25 - $92.52 $158,306 - $217,792
2,354 New
2,354 $204,000

Others Institutions Holding FATE

# of Institutions
175
Shares Held
115M
Call Options Held
53.7K
Put Options Held
9K
View Full List

About FATE THERAPEUTICS INC

FATE Quotes by TradingView
  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $157M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Profund Advisors LLC Portfolio

Follow Profund Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Profund Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email